Bie Li-Zhan, Wu Chao, Wang Jia-Lu
Department of Cardiology, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng 224000, Jiangsu Province, China.
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200020, China.
World J Hepatol. 2025 Jun 27;17(6):107931. doi: 10.4254/wjh.v17.i6.107931.
Improving our understanding of whether increased dietary intake of ω-3 polyunsaturated fatty acids (PUFAs) is beneficial for increasing skeletal muscle mass in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) could provide an important clinical evidence base for the development of relevant nutritional guidelines.
To investigate the effect of total dietary ω-3 PUFAs and their subtypes on skeletal muscle mass in MAFLD.
This cross-sectional study involved 2316 participants from four National Health and Nutrition Examination Survey cycles between 2011 and 2018. Dietary intake of ω-3 PUFAs was collected through 24-hour dietary recall interviews. Appendicular skeletal muscle mass index (ASMI) was calculated by dividing ASM in kilograms by height squared.
The multiple linear regression model showed significant relationships for dietary intake of total ω-3 PUFAs with higher ASMI (β: 0.06, 95%CI: 0.01-0.11) in MAFLD patients. Dietary a-linolenic acid (ALA) (β: 0.06, 95%CI: 0.01-0.12), docosapentaenoic acid (β: 1.28, 95%CI: 0.01-2.54), and docosahexaenoic acid (DHA) (β: 0.19, 95%CI: 0.01-0.37) were significantly associated with higher ASMI, while intake of stearidonic acid and eicosapentaenoic acid did not improve ASMI. In patients with high probability of liver fibrosis, dietary intake of ALA was associated with higher ASMI (β: 0.11, 95%CI: 0.03-0.18). Stratified analysis found that DHA was associated with higher ASMI in patients with obesity and higher metabolic risk.
Increasing dietary intake of ω-3 PUFAs improved skeletal muscle health in patients with MAFLD. Patient with obesity and higher metabolic risk were more likely to benefit from intake of DHA.
深入了解增加膳食中ω-3多不饱和脂肪酸（PUFA）的摄入量是否有利于增加代谢功能障碍相关脂肪性肝病（MAFLD）患者的骨骼肌质量，可为制定相关营养指南提供重要的临床证据基础。
探讨膳食中总ω-3多不饱和脂肪酸及其亚型对MAFLD患者骨骼肌质量的影响。
这项横断面研究纳入了2011年至2018年期间四个国家健康与营养检查调查周期的2316名参与者。通过24小时膳食回顾访谈收集ω-3多不饱和脂肪酸的膳食摄入量。通过将以千克为单位的四肢骨骼肌质量（ASM）除以身高的平方来计算四肢骨骼肌质量指数（ASMI）。
多元线性回归模型显示，MAFLD患者膳食中总ω-3多不饱和脂肪酸的摄入量与较高的ASMI显著相关（β：0.06，95%置信区间：0.01-0.11）。膳食α-亚麻酸（ALA）（β：0.06，95%置信区间：0.01-0.12）、二十二碳五烯酸（β：1.28，95%置信区间：0.01-2.54）和二十二碳六烯酸（DHA）（β：0.19，95%置信区间：0.01-0.37）与较高的ASMI显著相关，而硬脂酸和二十碳五烯酸的摄入量并未改善ASMI。在肝纤维化可能性较高的患者中，膳食中ALA的摄入量与较高的ASMI相关（β：0.11，95%置信区间：0.03-0.18）分层分析发现，DHA与肥胖和代谢风险较高的患者中较高的ASMI相关。
增加膳食中ω-3多不饱和脂肪酸的摄入量可改善MAFLD患者的骨骼肌健康。肥胖和代谢风险较高的患者更有可能从DHA的摄入中获益。
